F

Fondazione Policlinico Universitario Agostino Gemelli | Dermatology Department

Research site

(Unclaimed)

Location

8 Largo Agostino Gemelli, Rome, Rome, Italy

Site insights

Top conditions

Top treatments

Tepotinib

Pembrolizumab

Platinum

KIN-3248

Cetuximab

Cilofexor

Debio 1143

Pamrevlumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 16 total trials

A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors

The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.

Active, not recruiting

Cutaneous Squamous Cell Carcinoma

Castration-resistant Prostate Cancer

Drug: Pembrolizumab

Drug: Nanrilkefusp Alfa

A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX)

The primary objective of the study is to demonstrate superior efficacy of Xevinapant (Debio 1143) vs placebo when added to chemoradiotherapy (CRT) in...

Active, not recruiting

Squamous Cell Carcinoma of the Head and Neck

Drug: Placebo

Drug: Xevinapant (Debio 1143)

A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-3248, an oral small molecul...

Active, not recruiting

Solid Tumor, Adult

Urothelial Carcinoma

Drug: KIN-3248